Physician profile
Christopher Robert Andrew
NPI 1184660995
$76,853.67
in general payments reported to CMS, 2019-2025
35 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $13K · 2021: $19K · 2022: $12K · 2023: $9,909 · 2024: $1,022 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,938 · Food and Beverage: $3,447 · Travel and Lodging: $786 · Education: $106 · Consulting Fee: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,938.00 |
| Food and Beverage | $3,446.58 |
| Travel and Lodging | $786.00 |
| Education | $105.95 |
| Consulting Fee | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $73,113.88 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Teva Pharmaceuticals USA, INC. | $678.31 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $523.23 | 2020-2025 | |
| Emd Serono, INC. | $399.30 | 2019-2024 | Mavenclad |
| Abbvie INC. | $340.80 | 2021-2025 | Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $297.65 | 2021-2025 | Rexulti |
| Ucb, INC. | $199.48 | 2023-2025 | Rystiggo, Bimzelx |
| Novartis Pharmaceuticals Corporation | $147.79 | 2019-2025 | |
| Argenx US, INC. | $131.92 | 2024 | Vyvgart Hytrulo |
| Genzyme Corporation | $118.40 | 2019-2025 | |
| Bioventus LLC | $99.15 | 2023 | Sonicone Clinic |
| Pfizer INC. | $94.22 | 2024-2025 | |
| Celgene Corporation | $74.86 | 2021-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $57.04 | 2024-2025 | |
| Lilly USA, LLC | $55.04 | 2021-2024 | Amyvid, Mounjaro |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $42.63 | 2022-2025 | Vyepti |
| Allergan, INC. | $42.50 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $42.33 | 2025 | Ponvory |
| Novo Nordisk INC | $41.28 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Acadia Pharmaceuticals INC | $34.17 | 2025 | Daybue |
| Csl Behring | $31.63 | 2025 | Hizentra |
| Sobi, INC | $29.61 | 2025 | |
| Ani Pharmaceuticals, INC. | $29.00 | 2025 | Purified Cortrophin Gel |
| Sk Life Science, INC. | $25.98 | 2024 | |
| Averitas Pharma INC. | $24.46 | 2025 | Qutenza |
| Aurinia Pharma U.S., INC. | $24.09 | 2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $21.89 | 2024 | Saphnelo |
| Acorda Therapeutics, INC | $20.15 | 2019 | |
| Axsome Therapeutics, INC. | $19.08 | 2025 | Symbravo |
| Kedrion Biopharma, INC. | $18.04 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Koate |
| Grifols USA, LLC | $17.27 | 2025 | Gamunex-C |
| Janssen Biotech, INC. | $16.23 | 2024 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $15.15 | 2025 | Hyqvia |
| Cycle Pharmaceuticals INC | $14.42 | 2025 | Tascenso Odt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Andrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.